Ergoteles’s Atossa Therapeutics ATOS Stock Holding History

Ergoteles’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-21,084	Closed	-$264K	–	1439
2022 Q3	$264K	Sell	21,084 -13,223	-39%	-$192K	0.01%	1041
2022 Q2	$561K	Buy	+34,307	New	+$541K	0.02%	792

Other funds holding ATOS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Ergoteles's ATOS Position: Q4 2022 in Review

Ergoteles sold out of Atossa Therapeutics (ATOS) in Q4 2022, closing a stake of 21,084 shares — an estimated $264K sold.

Ergoteles first reported a position in ATOS in Q2 2022 and held it in 2 quarters. The position peaked at $561K in Q2 2022. 51 funds tracked by Wall St. Rank hold ATOS as of Q4 2022.

Ergoteles reported no remaining Atossa Therapeutics position as of Q4 2022 after selling out during the quarter.
Ergoteles sold 21,084 Atossa Therapeutics shares in Q4 2022, an estimated $264K.
Ergoteles first reported a position in Atossa Therapeutics in Q2 2022 and held it in 2 quarters.
Ergoteles's Atossa Therapeutics position peaked at $561K in Q2 2022.
51 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.